Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 133

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 133
---

effect on our business.

The patent position of biotechnology and pharmaceutical companies generally
is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The
standards that the U.S. Patent and Trademark Office (the “USPTO”) and its counterparts in other countries use to grant
patents are not always applied predictably or uniformly. In addition, the laws of countries other than the United States may not
protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems
in protecting and defending such rights in such jurisdictions. For example, European patent law restricts the patentability of methods
of treatment of the human body more than United States law does.

Other parties have developed technologies that may be related or competitive
to our own technologies and such parties may have filed or may file patent applications, or may have received or may receive patents,
claiming inventions that may overlap or conflict with those claimed in our own or licensed patent applications or issued patents. Furthermore,
publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot
know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending
patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance,
scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications
may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent
others from commercializing competitive technologies and product candidates. Changes in either the patent laws or interpretation of the
patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.

Patent reform legislation in the United States, including the
Leahy-Smith America Invents Act (the “Leahy-Smith Act”), could increase those uncertainties and costs surrounding
the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act made significant
changes to U.S. patent law, including the way patent applications are prosecuted, redefined prior